NEW YORK (GenomeWeb) – CompanionDx Reference Lab announced a deal on Monday with RegenWell Holdings to bring CompanionDx's tests to the point-of-care setting.
The deal will provide RegenWell, a Georgia-based, integrated healthcare provider, access to CompanionDx's pharmacogenomics, cancer companion diagnostics, targeted next-generation sequencing, and epigenomics testing.
"This partnership is indicative of the trend in healthcare to create synergistic relationships which enable better healthcare options for patients," CompanionDx Senior Vice President of Sales Nikko Khazana said in a statement. "Through the CompanionDx Lab and RegenWell alliance, we are expanding the opportunity to use personal genomic information in patient care and therapeutic decision-making."
Financial and other terms of the deal were not disclosed.
CompanionDx is a high-complexity CLIA-certified laboratory, and has forged deals recently with Rx Review Service and Enable Healthcare to increase the use of pharmacogenomics testing.